DEALS
Zhong Lun Assists SSCI Leading Fund in Leading the Investment in Vitalgen
Zhong Lun Assists SSCI Leading Fund in Leading the Investment in Vitalgen
Recently, Shanghai SSCI Leading Private Equity Fund Management Co., Ltd. ("SSCI Leading Fund") acted as the lead investor and completed the Series C financing of Shanghai Vitalgen BioPharma Co., Ltd. ("Vitalgen") together with its sub-fund Loyal Valley Capital and other well-known investment institutions. This investment represents a significant milestone for SSCI Leading Fund as it strengthens its strategic presence in cell and gene therapy (CGT) within the biopharmaceutical ecosystem. Moreover, it exemplifies how state-owned capital may leverage "patient capital" to empower cutting-edge medical innovation and drive breakthroughs in China-originated innovative drugs in the field of gene therapy. It also injects strong impetus into Shanghai's efforts to build a world-leading highland for biopharmaceutical innovation.
Zhong Lun Law Firm acted as the legal advisor to SSCI Leading Fund in this project, providing comprehensive legal services including conducting legal due diligence on Vitalgen, as well as reviewing and revising transaction documents, and assisting with the closing process. The project was led by partners Mo Xu and Yinzi Hu. Team members included associates Wenlong Yang and Fangxu Liu, as well as Zhewei Yu.
